Article

Ophthalmic viscosurgical device recalled by FDA after reports of toxic anterior segment syndrome

The FDA has recalled one lot of an ophthalmic viscosurgical device ([OVD] Healon D, Advanced Medical Optics [AMO]) following a voluntary recall by the manufacturer. The lot number, UD30654, is displayed on the side panel of each unit.

Key Points

Rockville, MD-The FDA has recalled one lot of an ophthalmic viscosurgical device ([OVD] Healon D, Advanced Medical Optics [AMO]) following a voluntary recall by the manufacturer. The lot number, UD30654, is displayed on the side panel of each unit.

AMO voluntarily recalled all 4,439 units of the lot Oct. 30 after receiving complaints of inflammation after eye surgery, including toxic anterior segment syndrome (TASS). At that time, the company informed customers of the lot number and nature of adverse event reports and included a fax reply form for communication with the firm. As of Dec. 3, however, AMO had retrieved only 964 units of the 1,450 that had been distributed in the United States, according to the FDA.

AMO received 66 adverse event reports associated with the recalled product. Tests of the lot revealed elevated levels of endotoxin. FDA spokeswoman Siobhan DeLancey said the FDA characterizes the action as a Class I recall because the lot poses a "significant potential for harm to human health." The delayed classification merely restates the company's voluntary recall, she said.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.